NanoBone is a bone graft substitute that harnesses the body’s own capacity to heal bone. It heals as well as autograft – with lower risk.

Diagnostic cardiology device start-up.

Marketing, Business Development and Clinical consulting in MedTech / medical devices emerging companies. Specialized in start-up ventures, early-stage direct-to-patient marketing, Clinical Marketing, Market Development, commercialization planning and execution.Clients:* Pulsator Irrigation (2021-present): High efficiency irrigation.* NanoBone (2020-present): Orthopedic bone graft substitute start-up.* Sandstone Diagnostics (2019): Blood plasma, cell-free DNA diagnostic start-up.* Empirical Spine (2018-2019): LimiFlex, lumbar fusion alternative start-up.* SpineEX, Inc. (2018-2020): Spine start-up with expandable adjustable interbody.* Zenflow (2018): BPH treatment start-up.* Bullseye Ortho (2018-2019): Orthopedic surgical planning start-up.* Novonate (2018): Advisor, neonatal start-up.* CuraSeal (2014-2017): Commercial advisory role, fistula start-up.* Siesta Medical (2015-2017): Sleep apnea start-up.* MicroPort Ortho (2014-2015): Marketing advisor, orthopedic surgical devices company.* Benvenue Medical (2012-2015): Marketing advisory role, spine.* TVA Medical (2013-2014): Advisor, endovascular start-up company.* Zyga (2013-2014): Marketing advisor, MIS SI joint fusion start-up company.* Rhausler Spine (2012-2015): Advisor, cervical spine company.* EPIX Ortho (2012-present): Commercial advisor, variable angle hip nail.* IlluminOss (2013-2014): Advisor, start-up orthopaedic trauma company.* U&i Corporation (2014-2015): Commercial advisor, surgical devices.* Pelvalon (2013): Advisor, Female incontinence.* Invuity (2013): Clinical Marketing consulting, surgical illumination company.* SpineGuard (2012-2014): Clinical Marketing, spine surgery safety.* OrthoKinematics (2007-9): Spinal diagnostic start-up.* Vascular Control Systems (2004-5): VP Clinical Marketing, gynecology start-up sold to JNJ.* Skeletal Kinetics (2003-2010): Orthopedic bone void filler company.* Prenatek (2006-7): Advisor, pregnancy monitoring start-up.

Award winning Sonoma Coast AVA Pinot Noir from Dijon clones 115, 667, and 777, plus Pommard. Partner wineries: Flowers, Macrostie, Foley-Banshee, Paper Plane, Domaine Carneros, Saxon Brown, Black Kite, Ramsgate, and Deerfield Ranch.

Alio is noninvasive remote monitoring for complications in dialysis patients, providing the right data at the right time in one place.

* Responsible for growing & scaling go-to-market and direct-to-patient strategy.* Successfully managing complexities involved in launching surgical devices into healthcare markets* Responsible for re-positioning Tensor and focusing on value-based medicine.* Providing Marketing focus on clinical and cost-efficacy of shoulder repair surgery.

Marketing and clinical support for commercialization of sacroiliac joint fusion products - comprehensive direct-to-patient and surgeon approach with lateral, posterior and hybrid devices using self-harvesting autograft technology.

Lumbar fusion alternative for degenerative spondylolisthesis patients undergoing PMA clinical trial.

SimpleTherapy is an online program which allows individual users to perform exercise and physical therapy (PT) exercises anywhere and anytime by watching a series of personalized and adaptive videos using artificial intelligence (AI). Consulting role in business Development.

Consulting marketing executive with MRI-compatible cervical arthroplasty device.

Medical device incubator company with core technology in protein crosslinking.

SF Bay Area start-up medical device company with sacroiliac joint fusion system (spine).Responsible for global marketing, strategic planning, commercialization support, clinical marketing, presentation and publication strategy, managing surgeon advisory board & post-market surveillance. A Mark Reiley, MD (Kyphon), company.

Public diagnostic products company. Cholestech acquired by Inverness in 2007.* Managed cross-SBU business development in meter, lateral flow, nucleic acid platforms.* Focus in CV, oncology, drugs of abuse, infectious disease & home disease management. * Managed cardiology joint development project with Israeli start-up diagnostic company. * Established/managed major clinical trial in chest pain units and directed product launch.

Private company with NIR spectroscopy and vascular / ortho / plastic surgery products. * Contract VP of Marketing.* Developed strategic plan and positioned company for private investment.

Early-stage interventional cardiology device company. Company was sold to Kensey Nash.• Responsible for business development, strategic planning, clinical and product marketing.• Managed four-person marketing team in successful new guidewire launch.

Endovascular company founded by Dr. Fogarty. Company was sold to SSI. * Hired by Allan May to develop business plan and position company for successful exit. * Responsible for successful launch of new endovascular surgical tools and covered stent. * Developed, implemented reimbursement plan.

Private company using novel cross-linking technology to develop in situ, bioresorbable coronary and vascular stents.

Development-stage company focused on interventional vascular treatment for calcification of aortic valve and vascular lesions. Company sold to Cordis-JNJ.• Responsible for distribution, licensing, and corporate partnerships, • Negotiated corporate partnership with Cordis Corporation (JNJ),• Raised $11.0 million in financing in 2000 and 2001.

Managed international clinical marketing for ventricular assist device and for coronary and Vectra vascular access grafts.* Grew business by 25% in first year of VAD launch in EU.

Managed clinical marketing for AngioJet, Perma-Flow and Perma-Seal.* Managed clinical trials to obtain 3 vascular regulatory approvals in 1995-6.* Licensed Perma-Flow to Baxter-Edwards.* Licensed Perma-Seal to Bard-Impra.

Managed international clinical marketing for vascular device business unit.* Grew vascular business unit from $0 to $5 million in 4 years.